Global Blood Therapeutics (NASDAQ: GBT) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.
Institutional and Insider Ownership
86.1% of Global Blood Therapeutics shares are held by institutional investors. Comparatively, 83.3% of Esperion Therapeutics shares are held by institutional investors. 5.3% of Global Blood Therapeutics shares are held by insiders. Comparatively, 32.5% of Esperion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Global Blood Therapeutics and Esperion Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Global Blood Therapeutics||N/A||N/A||-$95.43 million||($2.47)||-13.32|
|Esperion Therapeutics||N/A||N/A||-$131.29 million||($5.78)||-9.03|
Global Blood Therapeutics is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent ratings and recommmendations for Global Blood Therapeutics and Esperion Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Global Blood Therapeutics||0||0||11||0||3.00|
Global Blood Therapeutics presently has a consensus target price of $55.73, suggesting a potential upside of 69.38%. Esperion Therapeutics has a consensus target price of $59.09, suggesting a potential upside of 13.18%. Given Global Blood Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Global Blood Therapeutics is more favorable than Esperion Therapeutics.
This table compares Global Blood Therapeutics and Esperion Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Global Blood Therapeutics||N/A||-38.92%||-36.49%|
Risk & Volatility
Global Blood Therapeutics has a beta of 4.21, meaning that its stock price is 321% more volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 2.67, meaning that its stock price is 167% more volatile than the S&P 500.
Global Blood Therapeutics beats Esperion Therapeutics on 9 of the 10 factors compared between the two stocks.
Global Blood Therapeutics Company Profile
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company’s GBT440 is an investigational drug that increases hemoglobin’s affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.
Receive News & Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related companies with our FREE daily email newsletter.